PMV Pharmaceuticals, Inc.
PMVP
$1.56
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.85% | -13.06% | -14.54% | -12.65% | -13.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.20% | 8.82% | 11.21% | 7.73% | -2.38% |
| Operating Income | -10.20% | -8.82% | -11.21% | -7.73% | 2.38% |
| Income Before Tax | -6.83% | -25.66% | -27.57% | -21.62% | -8.48% |
| Income Tax Expenses | 86.51% | 86.35% | 86.90% | -609,966.67% | -536,733.33% |
| Earnings from Continuing Operations | -32.42% | -60.70% | -65.45% | 6.49% | 14.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.42% | -60.70% | -65.45% | 6.49% | 14.87% |
| EBIT | -10.20% | -8.82% | -11.21% | -7.73% | 2.38% |
| EBITDA | -11.67% | -10.71% | -12.73% | -8.72% | 2.27% |
| EPS Basic | -30.14% | -58.50% | -61.45% | 11.14% | 21.28% |
| Normalized Basic EPS | -16.12% | -15.25% | -16.12% | -7.00% | 9.26% |
| EPS Diluted | -30.14% | -58.50% | -61.45% | 11.14% | 21.28% |
| Normalized Diluted EPS | -16.12% | -15.25% | -16.12% | -7.00% | 9.26% |
| Average Basic Shares Outstanding | 1.86% | 1.40% | 1.96% | 4.62% | 7.44% |
| Average Diluted Shares Outstanding | 1.86% | 1.40% | 1.96% | 4.62% | 7.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |